Zhejiang East-Asia Pharmaceutical Co (SHSE:605177) Additional Paid-In Capital : ¥0 Mil(As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is Zhejiang East-Asia Pharmaceutical Co Additional Paid-In Capital?

Zhejiang East-Asia Pharmaceutical Co's quarterly additional paid-in capital increased from Sep. 2024 (¥0 Mil) to Dec. 2024 (¥1,117 Mil) but then stayed the same from Dec. 2024 (¥1,117 Mil) to Mar. 2025 (¥0 Mil).

Zhejiang East-Asia Pharmaceutical Co's annual additional paid-in capital stayed the same from Dec. 2022 (¥1,129 Mil) to Dec. 2023 (¥1,129 Mil) but then declined from Dec. 2023 (¥1,129 Mil) to Dec. 2024 (¥1,117 Mil).

Zhejiang East-Asia Pharmaceutical Co Additional Paid-In Capital Historical Data

The historical data trend for Zhejiang East-Asia Pharmaceutical Co's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhejiang East-Asia Pharmaceutical Co Additional Paid-In Capital Chart

Zhejiang East-Asia Pharmaceutical Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Additional Paid-In Capital

Get a 7-Day Free Trial

1,128.66

1,117.30

Zhejiang East-Asia Pharmaceutical Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Additional Paid-In Capital	Get a 7-Day Free Trial															-	1,151.75	-	1,117.30	-

Zhejiang East-Asia Pharmaceutical Co Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Zhejiang East-Asia Pharmaceutical Co Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Zhejiang East-Asia Pharmaceutical Co's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Zhejiang East-Asia Pharmaceutical Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zhejiang East-Asia Pharmaceutical Co Ltd (SHSE:605177) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 118, Laodong North Road, 23rd Floor, Chamber of Commerce Building, Huangyan District, Zhejiang Province, Taizhou, CHN

Website

http://www.eapharm.cn

Zhejiang East-Asia Pharmaceutical Co Ltd is mainly engaged in the production of bulk pharmaceutical chemicals, tablets, granules and capsules. The company's main products are: Ofloxacin, levofloxacin, loratadine hydrochloride, levofloxacin hydrochloride, trimebutine maleate, ketoconazole, terbinafine hydrochloride, piperazine, ticlazole and so on.

Zhejiang East-Asia Pharmaceutical Co Headlines

No Headlines